ImmunoCellular Therapeutics Provides Update on ICT-107 Phase 3 Glioblastoma Trial and Announces Advances in Stem-to-T-Cell Research Program

LOS ANGELES, March 6, 2017 /PRNewswire/ — ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT:IMUC) today provided an update on the Company’s ICT-107 phase 3 registration trial in newly diagnosed glioblastoma, and announced advances in its Stem-to-T-cell Research program.